Altimmune, Inc. (ALT)

Market Cap	625.33M
Revenue (ttm)	20,000
Net Income (ttm)	-90.24M
Shares Out	81.11M
EPS (ttm)	-1.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,498,072
Open	7.24
Previous Close	7.19
Day's Range	6.89 - 7.73
52-Week Range	3.55 - 11.16
Beta	0.57
Analysts	Strong Buy
Price Target	21.00 (+172.37%)
Earnings Date	Aug 7, 2025

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ALT
• Website: https://altimmune.com

Financial Performance

In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 172.37% from the latest price.

Price Target

$21.0

(172.37% upside)

Analyst Consensus: Strong Buy